Goserelin to remain available to NZers
People with prostate cancer and breast cancer will continue to have fully funded access to the hormonal treatment
goserelin (Zoladex) following an agreement between Government drug-funding agency PHARMAC and pharmaceutical company
PHARMAC Medical Director Dr Peter Moodie says he is pleased that patients will continue to have access to the medicine
following discussions between PHARMAC and AstraZeneca, while savings are maintained for taxpayers.
Both the one and three-month preparations of goserelin and leuprorelin will continue to be fully funded in the GnRH
analogues therapeutic group.
Dr Moodie says the agreement with AstraZeneca is verbal, and subject to contracting and final approval.